Research Topics
Species | Larissa A WenningSummaryAffiliation: Merck Research Laboratories Country: USA Publications
| Collaborators
|
Detail Information
Publications
Pharmacokinetics of famotidine in infantsLarissa A Wenning
Merck Research Laboratories, West Point, Pennslyvania, USA
Clin Pharmacokinet 44:395-406. 2005..Little is currently known about the pharmacokinetics of famotidine in infants aged between 1 month and 1 year, a period when renal function is maturing...- Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravirLarissa A Wenning
Merck and Co, Inc, Whitehouse Station, New Jersey, USA
Antimicrob Agents Chemother 53:2852-6. 2009..Coadministration of rifampin and raltegravir is not contraindicated; however, caution should be used, since raltegravir trough concentrations in the presence of rifampin are likely to be at the lower limit of clinical experience... - Lack of a significant drug interaction between raltegravir and tenofovirLarissa A Wenning
Merck and Co, Inc, Whitehouse Station, New Jersey, USA
Antimicrob Agents Chemother 52:3253-8. 2008..87, 0.90, and 0.77, respectively. Coadministration of raltegravir and TDF does not change the pharmacokinetics of either drug to a clinically meaningful degree. Raltegravir and TDF may be coadministered without dose adjustments... - Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphismsL A Wenning
Department of Drug Metabolism, Merck Research Laboratories, a division of Merck and Co, Inc, Whitehouse Station, New Jersey, USA
Clin Pharmacol Ther 85:623-7. 2009..This increase is not clinically significant, and therefore no dose adjustment of raltegravir is required for individuals with the UGT1A1*28/*28 genotype... - Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravirMarian Iwamoto
Merck Research Laboratories, P O Box 2000, Rahway, NJ 07065 0900, USA
Antimicrob Agents Chemother 52:4338-43. 2008..No dose adjustment is required for raltegravir with coadministration with ritonavir or efavirenz... - Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlationMarian Iwamoto
Merck and Co, Inc, Whitehouse Station, NJ, USA
J Clin Pharmacol 48:209-14. 2008.... - Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy womenMatt S Anderson
Merck Research Labs, Merck and Co, Inc, Whitehouse Station, NJ 07065 0900, USA
Br J Clin Pharmacol 71:616-20. 2011.... - Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlationDiana M Brainard
Merck and Co, Inc, 126 E Lincoln Ave, P O Box 2000, Rahway, NJ 07065, USA
J Clin Pharmacol 51:943-50. 2011..80 (0.68-0.94); and GMR of time to maximal concentration (C(max)) and 90% CI was 1.39 (0.87-2.21). Overall, coadministration of rifabutin did not alter raltegravir pharmacokinetics to a clinically meaningful degree... - Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokineticsMarian Iwamoto
Merck and Co, Inc, Whitehouse Station, New Jersey, USA
Antimicrob Agents Chemother 53:1747-52. 2009..No adjustment in the dose of raltegravir is required for patients with mild or moderate hepatic or renal insufficiency... - Effects of omeprazole on plasma levels of raltegravirMarian Iwamoto
Merck and Co, Whitehouse Station, Rahway, NJ 07065 0900, USA
Clin Infect Dis 48:489-92. 2009..Increased gastric pH has been reported in HIV-1-infected individuals, and the effects of omeprazole in this intended population may be diminished. Further investigation is necessary... - Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjectsMatt S Anderson
Department of Clinical Pharmacology, Merck and Co, Inc, RY34A 500, P O Box 2000, Rahway, NJ 07065, USA
Antimicrob Agents Chemother 52:4228-32. 2008..Coadministration of etravirine and raltegravir was generally well tolerated; the data suggest that no dose adjustment for either drug is necessary... - Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitorDiana M Brainard
Merck Sharp and Dohme Corp, Whitehouse Station, New Jersey, USA
J Clin Pharmacol 51:1376-402. 2011.... - Effect of tipranavir-ritonavir on pharmacokinetics of raltegravirWilliam D Hanley
Merck and Co, Inc, Whitehouse Station, New Jersey, USA
Antimicrob Agents Chemother 53:2752-5. 2009..Although the RAL C(12) was decreased with TPV-RTV in this study, favorable efficacy data collected in phase III studies substantiate that TPV-RTV may be coadministered with RAL without dose adjustment... - Effect of raltegravir on the pharmacokinetics of methadoneMatt S Anderson
Merck and Co, Inc, Whitehouse Station, NJ, USA
J Clin Pharmacol 50:1461-6. 2010..Coadministration of raltegravir and methadone is generally well tolerated. Raltegravir has no clinically meaningful effect on methadone pharmacokinetics. No dose adjustment is required for methadone when coadministered with raltegravir... - Atazanavir modestly increases plasma levels of raltegravir in healthy subjectsMarian Iwamoto
Merck, Whitehouse Station, RY34 A500, PO Box 2000, Rahway, NJ 07065 0900, USA
Clin Infect Dis 47:137-40. 2008..Atazanavir and atazanavir plus ritonavir modestly increase plasma levels of raltegravir... - Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentariumBach Yen T Nguyen
ISENTRESS Discovery and Development Team, Merck Research Laboratories, North Wales, Pennsylvania 19454 1099, USA
Ann N Y Acad Sci 1222:83-9. 2011..Raltegravir represents an important addition to the current armamentarium for the treatment of HIV infection... - Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzymeKelem Kassahun
Department of Drug Metabolism, WP75B 200, Merck Research Laboratories, P O Box 4, West Point, PA 19486, USA
Drug Metab Dispos 35:1657-63. 2007..Collectively, the data indicate that the major mechanism of clearance of raltegravir in humans is UGT1A1-mediated glucuronidation... - Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled studyMartin Markowitz
Aaron Diamond AIDS Research Center, Rockefeller University, New York, NY, USA
J Acquir Immune Defic Syndr 46:125-33. 2007..This study explored the antiretroviral activity and safety of raltegravir in treatment-naive patients with plasma HIV-1 RNA levels > or = 5000 copies/mL and CD4 T-cell counts > or = 100 cells/mm...